|
30 Oct 2019 |
TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction
|
|
28 Oct 2019 |
Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS)
|
|
28 Oct 2019 |
IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
|
|
26 Oct 2019 |
VISEN Pharmaceuticals announces China Phase 3 clinical study initiation for TransCon human growth hormone, the first unmodified long-acting growth hormone in China
|
|
25 Oct 2019 |
Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS
|
|
25 Oct 2019 |
FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
|
|
21 Oct 2019 |
OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
|
|
17 Oct 2019 |
Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
|
|
16 Oct 2019 |
Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
|
|
16 Oct 2019 |
Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
|
|
16 Oct 2019 |
Aro Biotherapeutics Debuts Lead Centyrin Candidate at 2019 OTS Meeting
|
|
15 Oct 2019 |
AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
|
|
14 Oct 2019 |
DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
|
|
12 Oct 2019 |
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
|
|
10 Oct 2019 |
Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
|
|
08 Oct 2019 |
FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
|
|
08 Oct 2019 |
FDA Approves Octapharma’s WILATE® for Hemophilia A in Adult and Adolescent Patients
|
|
08 Oct 2019 |
Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
|
|
08 Oct 2019 |
Intarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650
|
|
08 Oct 2019 |
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
|
|
08 Oct 2019 |
Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
|
|
08 Oct 2019 |
Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957
|
|
03 Oct 2019 |
Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy
|
|
02 Oct 2019 |
Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
|
|
02 Oct 2019 |
Evolus Receives Approval for Nuceiva™ in the European Union
|
